We are equipped with specialized manufacturing capabilities including hydrogenation, cryogenic reactions, high temperature reactions etc. Some of our intermediates on offer are listed below
We are the leading manufacturer & exporter of a broad ranger of pharmaceutical intermediates which are extensively used in various pharmaceutical companies & research laboratories. Using high quality chemicals these intermediates are manufactured which ensure efficacy and no side effect on human health. We offer standard as well as customized packaging on these products to exactly meet the users requirements specifications.
Pharmaceutical intermediates have been essential in reducing the COVID-19 pandemic and will continue to be fundamental in preventing both further waves of this pandemic and future outbreaks of infectious diseases. According to a study that was published in the American Chemical Society Pharmacology and Translational Science, 2020, new potential therapeutics for COVID-19 were discovered using a combined virtual and experimental screening strategy. Furthermore, they choose among the medications that were already in use and were examined to check for structural similarity against a library of almost 4,000 medications that were already in use, with hydroxychloroquine (HCQ) serving as a reference medication. The study suggested remdesivir and favipiravir therapies as prospective adjuvants in COVID-19 treatment and zuclopenthixol, nebivolol, and amodiaquine as potential candidates for clinical trials against the early phase of the SARS-CoV-2 infection. Thus, the pharmaceutical intermediates market is likely to increase both during and after a covid pandemic. As a result, market growth is anticipated in the coming years.
Specific factors that are driving the market growth include the increasing prevalence of chronic diseases and growing R&D initiatives and activities in the pharmaceutical industry. Given that these pharma intermediates are used in the treatment for cancer detection and a variety of chronic diseases, the rise in the prevalence of chronic diseases is projected to propel market expansion in the area under study. For instance, chronic diseases account for around 41 million annual fatalities, or 71% of all fatalities worldwide, according to the World Health Organization's key facts on non-communicable diseases published in April 2021. The high fatality rate from these diseases increases the demand for early intervention, which in turn propels the market's expansion.
Specific factors that are driving the market growth include the increasing prevalence of chronic diseases and growing R&D initiatives and activities in the pharmaceutical industry. Given that these pharma intermediates are used in the treatment for cancer detection and a variety of chronic diseases, the rise in the prevalence of chronic diseases is projected to propel market expansion in the area under study. For instance, chronic diseases account for around 41 million annual fatalities, or 71% of all fatalities worldwide, according to the World Health Organization's key facts on non-communicable diseases published in April 2021. The high fatality rate from these diseases increases the demand for early intervention, which in turn propels the market's expansion.